The European Commission approved an additional dosing regimen for Chiesi and Protalix’s Elfabrio (pegunigalsidase alfa) in adults with Fabry disease who are stable on enzyme replacement therapy. The regimen is 2 mg/kg every four weeks. Protalix is entitled to a USD 25 million regulatory milestone payment from Chiesi tied to the approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603090600PRIMZONEFULLFEED9668145) on March 09, 2026, and is solely responsible for the information contained therein.